A Change of Heart for the S&P Top 10

Coronary-stent maker Boston Scientific replaces Constellation Brands in the portfolio of S&P's best investment ideas

On Jan. 30, Standard & Poor's equity research group made a change to the S&P Top 10 portfolio -- those issues it considers to be the best candidates for capital gains over the next 6 to 12 months. Medical-device maker Boston Scientific (BSX ) has been tapped to replace wine and spirits producer Constellation Brands (STZ ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.